Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC <a target=_blank href=http ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

"A highlight of the third quarter was the presentation of our validating COM701, COM902, pembrolizumab combination data in heavily pre-treated platinum resistant ovarian cancer (PROC ... more fully ...

Immunocore reports third quarter financial results and provides a business updateKIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q ...

BNT327/PM8002 is a bispecific antibody candidate combining Programmed Cell Death Ligand-1 (“PD-L1”) checkpoint inhibition with Vascular Endothelial Growth Factor A ... platinum-resistant ovarian ...

A recent study has developed a novel method to analyze genetic variations in families with a high incidence of breast cancer.

As of September 30, 2024, Zymeworks has repurchased 1,818,530 shares of the Company's common stock for a cost of $20.6 ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Staging of ovarian cancer has been routinely practiced by means of contrast-enhanced CT. The sensitivity of this technique depends on the size and location of peritoneal implants, owing to their ...